COMP <GO>
MDLN vs LLY // RSI-14 & 200D SMA MOMENTUM
Medline Inc. (NASDAQ) VS. Eli Lilly and Company (NYSE) • 15-METRIC TALLY: MDLN 5
— LLY 10
▲ RSI-14 & 200D SMA MOMENTUM LEADER: LLY
LAST: $32.12 (+0.38%) • MKT CAP: $42.07B
rsi-technicals
31.6
LAST: $1,417.54 (+3.19%) • MKT CAP: $1.33T
rsi-technicals
77.9
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (MDLN VS. LLY)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | MDLN | LLY | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 26.40% | 83.64% | -57.24 | LLY | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 8.20% | 32.36% | -24.16 | LLY | /roic <GO> |
| EV/EBITDA & P/E Valuation | 20.3x | 36.4x | -16.12 | MDLN | /valuation <GO> |
| Free Cash Flow Yield | 3.08% | 2.30% | +0.78 | MDLN | /fcf-yield <GO> |
| Operating Margin | 7.80% | 40.21% | -32.41 | LLY | /operating-margins <GO> |
| Net Profit Margin | 68.00% | 31.90% | +36.10 | MDLN | /net-margins <GO> |
| Revenue Growth (YoY) | 11.50% | 45.51% | -34.01 | LLY | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.49% | -0.49 | LLY | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 2.50 | 9.29 | -6.79 | LLY | /balance-sheet <GO> |
| Piotroski F-Score Quality | 5/9 | 9/9 | -4.00 | LLY | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 7.30% | 6.77% | +0.53 | LLY | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum ACTIVE | 31.6 | 77.9 | -46.32 | LLY | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.11 | 0.51 | +0.60 | MDLN | /macro-sensitivity <GO> |
| Forward P/E Multiple | 4.2x | 26.3x | -22.05 | MDLN | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $42.07B | $1.33T | -$1.29T | LLY | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | MDLN REV | LLY REV | MDLN GROSS % | LLY GROSS % | MDLN FCF | LLY FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $28.43B | $65.18B | 26.4% | 83.0% | $1.30B | $16.81B |
| FY 2024 | $25.51B | $45.04B | 27.3% | 81.3% | $1.42B | $8.82B |
| FY 2023 | $23.23B | $34.12B | 44.0% | 79.3% | $639.6M | $4.24B |
| FY 2022 | — | $28.54B | — | 76.8% | — | $7.59B |
| FY 2021 | — | $28.32B | — | 74.2% | — | $7.37B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
MDLN // BETA 1.11
LLY // BETA 0.51